日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab(PD-1抑制剂)联合贝伐单抗(贝伐单抗生物类似药)作为晚期肝细胞癌的一线治疗方案:一项随机2/3期试验

Zhao, Chuanhua; Zhang, Yanqiao; Wang, Gang; Zheng, Jinfang; Chen, Weiqing; Lu, Zheng; Zhuang, Li; Gu, Shanzhi; Han, Lei; Zheng, Zhendong; Yu, Zujiang; Yang, Yongsheng; Sun, Hongmei; Wei, Xiaoyong; Cheng, Ying; Lin, Hailan; Zhu, Bo; Wu, Guicheng; Lei, Kaijian; Wang, Wei; Wang, Yuwen; Chen, Kehe; Xu, Ximing; Zheng, Cuiping; Bi, Yanzhi; Ding, Sijuan; Zhang, Jingdong; Li, Wei; Liu, Hailong; Wang, Jun; Liu, Xianling; Du, Yangfeng; Cai, Lianming; Wang, Jingran; Luo, Zhanxiong; Xing, Baocai; Shen, Jie; Yang, Lin; Wu, Jianbing; Jiang, Ou; Peng, Zhigang; Liu, Xiuli; Cao, Bangwei; Shen, Liangfang; Xu, Aibing; Li, Aimin; Chen, Shaojun; Fu, Ting; Chen, Jian; Jin, Chuan; Zhang, Lei; Lv, Jun; Zhang, Chengwu; Zhang, Xiaoman; Wang, Yu; Su, Huo; Zhou, Qiang; Gai, Wenlin; Xie, Liangzhi; Xu, Jianming

eNAMPT/Ac-STAT3/DIRAS2 Axis Promotes Development and Cancer Stemness in Triple-Negative Breast Cancer by Enhancing Cytokine Crosstalk Between Tumor-Associated Macrophages and Cancer Cells.

eNAMPT/Ac-STAT3/DIRAS2 轴通过增强肿瘤相关巨噬细胞与癌细胞之间的细胞因子串扰来促进三阴性乳腺癌的发展和癌症干性

Zhang Lifen, Wang Lu, Xu Ziyao, Zhang Xingmei, Guan Shaoyu, Liu Zhe, Gu Shanzhi, Zhao Lin, Bai Weichao, Li Tian, Zhao Xinhan

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

比较乐伐替尼与贝伐单抗联合免疫检查点抑制剂和介入三联疗法治疗中国晚期肝细胞癌的疗效:CLEAP 2302 研究

Pan, Zhaolong; Liu, Dongming; Cao, Junbo; Fu, Linlin; Zhang, Xihao; Zhu, Xiaodong; Pan, Yangxun; Liu, Jianwei; Han, Chuangye; Jin, Renan; Shen, Shunli; Zhang, Xiaoyun; Liu, Hongzhi; Yang, Xiaobo; Hu, Kuan; Shi, Xiaoyi; Wang, Dongxu; Zhao, Yang; Zhong, Jianhong; Xiang, Bangde; Gu, Shanzhi; Li, Tao; Zhang, Shuijun; Zhou, Ledu; Zhao, Haitao; Zeng, Yongyi; Wen, Tianfu; Kuang, Ming; Liang, Xiao; Peng, Tao; Wang, Kui; Xu, Li; Li, Huikai; Song, Tianqiang; Sun, Huichuan; Zhang, Wei

[Retracted] Notch1 induces epithelial‑mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role

【已撤稿】Notch1诱导乳腺癌细胞发生上皮-间质转化并产生癌症干细胞表型,而STAT3发挥关键作用

Zhang, Xiaojin; Zhao, Xiaoai; Shao, Shan; Zuo, Xiaoxiao; Ning, Qian; Luo, Minna; Gu, Shanzhi; Zhao, Xinhan

Attitude of patients with liver cancer toward clinical drug trials: empirical qualitative research

肝癌患者对临床药物试验的态度:实证定性研究

Lu, Wen; Li, Juan; Gu, Shanzhi; Li, Jinhua

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study

对多纳非尼常见治疗相关不良事件及其与疗效的相关性进行分析:ZGDH3 研究的探索性分析

Bi, Feng; Qin, Shukui; Gu, Shanzhi; Bai, Yuxian; Chen, Zhendong; Wang, Zishu; Ying, Jieer; Lu, Yinying; Meng, Zhiqiang; Pan, Hongming; Yang, Ping; Zhang, Helong; Chen, Xi; Xu, Aibing; Cui, Chengxu; Zhu, Bo; Wu, Jian; Xin, Xiaoli; Wang, Jufeng; Shan, Jinlu; Chen, Junhui; Zheng, Zhendong; Xu, Li; Wen, Xiaoyu; You, Zhenyu; Ren, Zhenggang; Xu, Jianming; Du, Chengyou; Fan, Qingxia; Zhang, Longzhen; Tao, Min; Jiang, Da; Wang, Senming; Chen, Yongping; Sheng, Jifang; Zhuang, Xuelong; Wu, Jun

FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma

FLT3LG调节免疫细胞浸润并增强抗PD-1疗法在肺腺癌中的疗效

Zhao, Fengyu; Bai, Han; Liu, Yiwei; Gao, Shuoze; Yang, Chengcheng; Wu, Jie; Cheng, Hao; Ma, Jiao; Li, Yuanyuan; Ren, Hong; Fu, Junke; Gu, Shanzhi; Zhao, Xinhan; Qin, Sida

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

在PD-L1 TPS≥1%的晚期或转移性非小细胞肺癌患者中,一线治疗方案为卡瑞利珠单抗联合法米替尼:一项多中心、开放标签的II期试验结果

Ren, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia; Zhou, Caicun

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors

DP303c(一种靶向HER2的抗体药物偶联物)在HER2阳性实体瘤患者中的首次人体研究

Zhang, Jian; Du, Yiqun; Meng, Yanchun; Liu, Xiaojun; Mu, Yuxin; Liu, Yunpeng; Shi, Yehui; Wang, Jufeng; Zang, Aimin; Gu, Shanzhi; Liu, Tianshu; Zhou, Huan; Guo, Hongqian; Xiang, Silong; Zhang, Xialu; Wu, Suqiong; Qi, Huanhuan; Li, Mengke; Hu, Xichun

Turnover intention and its related factors of clinical research coordinator in Hunan, China: a cross-sectional study

中国湖南省临床研究协调员离职意愿及其相关因素:一项横断面研究

Li, Juan; Li, JinHua; She, ZhengDi; Guo, LiWen; Gu, ShanZhi; Lu, Wen